Brief: Brainsway says Deep TMS System Significantly Reduced Symptoms Scores
27/06/2019 17:42
June 27 (Reuters) - Brainsway Ltd BWAY.TA :
* NEW DATA PUBLISHED IN AMERICAN JOURNAL OF PSYCHIATRY
FURTHER
SUBSTANTIATES BRAINSWAY’S DEEP TMS SYSTEM FOR THE TREATMENT OF
PATIENTS WITH OBSESSIVE COMPULSIVE DISORDER
* BRAINSWAY LTD - FIRST NON-INVASIVE DEVICE FOR OCD ACHIEVES
45%
RESPONSE RATE AMONG PATIENTS AFTER ONE MONTH FOLLOW UP
* BRAINSWAY LTD - DEEP TMS SYSTEM SIGNIFICANTLY REDUCED
SYMPTOMS
SCORES COMPARED WITH PLACEBO
Source text for Eikon: ID:nGNX2R323D
Further company coverage: BWAY.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Brainsway
See all newsBrief: Brainsway Presents Positive Data From Largest Real-World Study Of Deep Tms™ In Patients With Comorbid Ptsd And Major Depressive Disorder
Brief: Brainsway Announces Minority-Stake Investment In Hopemark Health
Brief: Brainsway Announces New Minority-Stake Investment In Canadian Provider, Brainstim Health Inc.
Brief: Brainsway Announces Change In ADS-To-Ordinary Share Ratio
Brief: BrainsWay Announces FDA Approval of Neurolief’s Proliv™Rx Neuromodulation System for Major Depressive Disorder (MDD)